Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported its first quarter 2013 financial results and ongoing progress with IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and retaspimycin HCl, its potent and selective inhibitor of heat shock protein 90 (Hsp90).
Help employers find you! Check out all the jobs and post your resume.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported its first quarter 2013 financial results and ongoing progress with IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and retaspimycin HCl, its potent and selective inhibitor of heat shock protein 90 (Hsp90).
Help employers find you! Check out all the jobs and post your resume.
